Pyroptosis-Mediator GSDMD in Plasma: A Promising Biomarker for Early Diagnosis of Type 2 Diabetes
These findings suggest that plasma GSDMD not only reflects early metabolic abnormalities associated with type 2 diabetes but also holds promise as a therapeutic target to mitigate inflammatory responses and improve insulin resistance. Further large-scale clinical studies are warranted to validate its diagnostic utility and enhance clinical applications.
Authors
- Xuexin Liu (ORCID: https://orcid.org/0000-0001-9799-0730)
- Shiyu Hou
- Nan Ding (ORCID: https://orcid.org/0000-0003-3116-7498)
- Lijing Huo (ORCID: https://orcid.org/0009-0000-7417-6699)
- Jintian He (ORCID: https://orcid.org/0000-0002-7489-1163)
- Hairui Zhang (ORCID: https://orcid.org/0000-0001-5582-1066)
- Baohua Zhao
Institutions
- Hebei General Hospital (CN)
- Hebei Normal University (CN)
Publication Details
- Journal
- Diabetes Metabolic Syndrome and Obesity
- Published
- 2025-02-01
- DOI
- https://doi.org/10.2147/dmso.s502336
- Primary Topic
- Inflammasome and immune disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00